Loading stock data…
10x Genomics, Inc. (TXG)
$46.27-1.79 (-3.72%)
Market ClosedLast close Jul 24
10x Genomics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
10x Genomics, Inc. in the Healthcare sector is trading at $46.27 with a market capitalization of $4.1B. Wall Street consensus targets $41.54 (13 analysts), implying a -10.2% move over the next 12 months. The stock is currently near its 52-week high of $49.50, remaining 105.9% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -10.2% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $150.84M↓ | $166.03M↑ | $149.00M↓ | $172.91M↑ | $154.88M |
| Gross Profit | $106.18M↓ | $113.05M↑ | $100.31M↓ | $125.08M↑ | $105.44M |
| Operating Income | -$17.05M↑ | -$19.54M↑ | -$32.24M↓ | -$10.57M↑ | -$48.53M |
| Net Income | -$13.47M↑ | -$16.25M↑ | -$27.47M↓ | $34.54M↑ | -$34.36M |
Peer Comparison
JNJUNHPFE
Fundamentals
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.08B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.05
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.78%
Volume
Today's trading volume
2.67M
Recent News
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance patients have, in this case, an increase in uninsured individuals resulting from losses in health insurance exchange coverage. For HCA, this shift was significant, reducing pre-tax income by an estimated $400 million
Cathie Wood Dumps $39 Million Worth of AMD Stock
Cathie Wood Trims AMD to Fund Bigger SpaceX Bet
1 Cash-Producing Stock with Exciting Potential and 2 Facing Challenges
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
3 Russell 2000 Stocks We Steer Clear Of
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
Cathie Wood’s ARK Invest Doubles Down On Circle In Two Funds At Once, Trims Robinhood Again
ARK's purchases come as investors closely watch progress on U.S. crypto legislation, including the CLARITY Act and stablecoin regulation efforts.